SG11202002767RA - 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof - Google Patents

4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof

Info

Publication number
SG11202002767RA
SG11202002767RA SG11202002767RA SG11202002767RA SG11202002767RA SG 11202002767R A SG11202002767R A SG 11202002767RA SG 11202002767R A SG11202002767R A SG 11202002767RA SG 11202002767R A SG11202002767R A SG 11202002767RA SG 11202002767R A SG11202002767R A SG 11202002767RA
Authority
SG
Singapore
Prior art keywords
dihydropyrrolo
trisubstituted
pyrimidin
pyridin
derivatives
Prior art date
Application number
SG11202002767RA
Other languages
English (en)
Inventor
Shuchun Guo
Fusheng Zhou
Xiang Chen
Jinzhu Zhao
Dong Huang
Jing Xie
Changjiang Qiao
Wan He
Kai Zhang
Xi Chen
Jiong Lan
Original Assignee
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Yangtze River Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haiyan Pharmaceutical Technology Co Ltd, Yangtze River Pharmaceutical Group Co Ltd filed Critical Shanghai Haiyan Pharmaceutical Technology Co Ltd
Publication of SG11202002767RA publication Critical patent/SG11202002767RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202002767RA 2017-09-28 2018-08-03 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof SG11202002767RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710897909 2017-09-28
PCT/CN2018/098481 WO2019062329A1 (fr) 2017-09-28 2018-08-03 Dérivé 4,6,7-trisubstitué de 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one et son utilisation

Publications (1)

Publication Number Publication Date
SG11202002767RA true SG11202002767RA (en) 2020-04-29

Family

ID=65900477

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002767RA SG11202002767RA (en) 2017-09-28 2018-08-03 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof

Country Status (9)

Country Link
US (2) US11174254B2 (fr)
EP (1) EP3689871B1 (fr)
JP (1) JP6922085B2 (fr)
CN (3) CN114478544B (fr)
AU (1) AU2018342342B2 (fr)
CA (1) CA3077238C (fr)
DK (1) DK3689871T3 (fr)
SG (1) SG11202002767RA (fr)
WO (2) WO2019062328A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US20210395247A1 (en) * 2019-03-18 2021-12-23 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Btk inhibitors, pharmaceutically acceptable salts, polymorphs and application thereof
CN116096369A (zh) * 2020-09-01 2023-05-09 上海海雁医药科技有限公司 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
WO2022121900A1 (fr) * 2020-12-07 2022-06-16 南京明德新药研发有限公司 Composé de pyrrolopyridine et son application
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
PE20130188A1 (es) * 2009-12-23 2013-02-21 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
EP2723739B1 (fr) * 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Dérivés de 6-aza-isoindolin-1-one substitués
KR102272792B1 (ko) * 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
RU2019131017A (ru) 2013-10-21 2019-11-25 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов btk и их применение
ES2921874T3 (es) * 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
CN106536503B (zh) * 2014-04-18 2019-09-06 北京澳合药物研究院有限公司 一种酪氨酸激酶抑制剂及其用途
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
PL3236943T3 (pl) * 2014-12-24 2023-05-29 Principia Biopharma Inc. Kompozycje do krętniczo-czczego dostarczania leków
KR20180070695A (ko) 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Mnk1 및 mnk2의 이소인돌린, 아자이소인돌린, 디히드로인데논 및 디히드로아자인데논 억제제
CN107021963A (zh) * 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用

Also Published As

Publication number Publication date
JP6922085B2 (ja) 2021-08-18
WO2019062328A1 (fr) 2019-04-04
US20200048248A1 (en) 2020-02-13
CN110267954B (zh) 2022-05-10
AU2018342342A1 (en) 2020-04-16
CN114478544B (zh) 2023-06-16
AU2018342342B2 (en) 2021-01-07
US20200223846A1 (en) 2020-07-16
US11155546B2 (en) 2021-10-26
EP3689871B1 (fr) 2021-09-29
EP3689871A1 (fr) 2020-08-05
EP3689871A4 (fr) 2020-08-05
CA3077238C (fr) 2022-04-12
CN110366553A (zh) 2019-10-22
WO2019062329A1 (fr) 2019-04-04
CN114478544A (zh) 2022-05-13
CN110366553B (zh) 2022-04-15
DK3689871T3 (da) 2021-12-06
US11174254B2 (en) 2021-11-16
JP2020535170A (ja) 2020-12-03
CA3077238A1 (fr) 2019-04-04
CN110267954A (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
ZA201905456B (en) Pyrrolo[1,2-b]pyridazine derivatives
HK1244787A1 (zh) 作為吲哚胺2，3-二加氧酶和/或色氨酸2，3-二加氧酶抑制劑的新穎的5或8-取代的咪唑並[1，5-a]吡啶
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
ZA201902562B (en) Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
SG11202002767RA (en) 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
PT3712152T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
PL3371185T3 (pl) Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
HUE056996T2 (hu) Pirido[3,4-d]pirimidin származék és gyógyszerészetileg elfogadható sója
ZA201900236B (en) Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof
HRP20190013T1 (hr) Derivati 1,2-dihidro-3h-pirolo[1,2 -c]imidazol-3-ona i njihova uporaba kao antibakterijska sredstva
EP3546460A4 (fr) Composé pyrimido[5,4-b]indolizine ou pyrimido[5,4-b]pyrrolizine, son procédé de préparation et son utilisation
EP3723754A4 (fr) Composés imidazo[1,2-c]quinazolin-5-amine présentant des propriétés antagonistes du a2a
HK1256044A1 (zh) 吡啶並[1，2-a]嘧啶酮類似物、其晶型、其中間體及其製備方法
HK1259613A1 (zh) 新型5h-吡咯並[2，3-d]嘧啶-6(7h)-酮衍生物
EP3190111A4 (fr) Dérivés de pyrazolo[3,4-c]pyridine
IL269215A (en) Disubstituted imidazole[4,5-C]quinoline derivatives
IL253427A0 (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose